Matthew P. Goetz, MD
“WHAT’S IMPORTANT for clinicians to take away from this analysis is that there is clearly zero benefit of atezolizumab/nab-paclitaxel in patients with programmed cell death ligand 1 (PD-L1)-negative disease. In PD-L1–positive patients, the combination improves progression-free survival and overall survival,” stated Matthew P. Goetz, MD, of the Mayo Clinic, Rochester, Minnesota.
“In other tumor types, we can’t exclude a benefit of checkpoint inhibitor in PD-L1–negative tumors. These data demonstrate that for triple-negative breast cancer, PD-L1–positive expression is a firm biomarker for patient selection for atezolizumab/nab-paclitaxel in this population. However, we have a long way to go to improve outcomes for both patients with PD-L1–negative and PD-L1–positive triple-negative breast cancer patients,” he stated.
“This analysis firmly cements the need for PD-L1 testing in triple-negative breast cancer. If I were at the U.S. Food and Drug Administration, I would not approve this combination for PD-L1–negative patients,” Dr. Goetz commented. ■
DISCLOSURE: Dr. Goetz is a consultant/advisor for Eli Lilly, Biotheranostics, Genomic Health, Novartis, Eisai, Context Therapeutics, and Sermonix Pharmaceuticals; and has received research funding from Pfizer and Eli Lilly.
THE PHASE III IMpassion130 trial, first reported at the European Society for Medical Oncology (ESMO) 2018 Congress1 and published in The New England Journal of Medicine,2 found that the combination of front-line atezolizumab plus nab-paclitaxel significantly improved disease-free and overall...